Abscint
Abscint is a Belgium-based, clinical-stage spin-off of VUB developing radiolabeled single-domain antibody PET tracers (lead asset 68Ga-HER2 for breast cancer, plus ABSCINT-206 for cardiac sarcoidosis) for whole-body molecular imaging, currently pre-revenue and conducting a Phase IIb HERMIA trial.
- Company typePrivate
- Founded2022
- HeadquartersGanshoren, Belgium
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Abscint does
Abscint is a clinical-stage molecular imaging company developing in-vivo radiopharmaceutical diagnostics based on radiolabeled single-domain antibodies (sdAbs). Founded in 2022 as a spin-off of Vrije Universiteit Brussel (VUB), with research roots at the VIB-VUB Center for Inflammation Research, the company is headquartered in Liège, Belgium (legal entity registered in Ganshoren) and operates with 1–10 employees. Its platform uses 12–15 kDa sdAbs labeled with short-half-life radioisotopes (notably Gallium-68) that bind to specific cell-surface proteins, enabling whole-body PET/CT imaging within 60–90 minutes post-injection with low radiation dose and no patient hospitalization.
The company's lead asset, 68Ga-HER2 (also referenced as ABS011), is a HER2-targeted PET tracer for breast and gastric cancer that visualizes HER2 expression across all lesions, addressing intra-patient heterogeneity missed by single-site biopsies. It is currently in a Phase IIb clinical study (the HERMIA trial) at six Belgian academic centers, with Phase I/II results on 116 patients showing 91% lesion-level agreement with standard IHC/ISH diagnostics and a 34.4% rate of treatment-plan modification. A second pipeline program, ABSCINT-206, targets cardiac sarcoidosis. Abscint's IP rests on a US patent application (16/827,032) with a USPTO Notice of Allowance received in February 2023, licensed from VUB.
Commercially, Abscint is pre-revenue: 68Ga-HER2 has not received marketing authorization in any jurisdiction, and no pricing has been disclosed. Revenue mechanics are currently limited to a GMP-grade precursor access program supplying academic institutes, hospitals, and companies for investigator-initiated trials, with planned future revenue from commercial tracer sales and technology licensing post-approval. Total disclosed funding is approximately EUR 4 million across two rounds in December 2022 and September 2023, led by Noshaq and Qbic with participation from UZ Brussel, Kazoku, Trasis, Wallonie Entreprendre, and family offices.
Abscint firmographics
Firmographics- Name
- Abscint
- Legal name
- Abscint nv
- Website
- https://abscint.com/
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Abscint is a Belgium-based, clinical-stage spin-off of VUB developing radiolabeled single-domain antibody PET tracers (lead asset 68Ga-HER2 for breast cancer, plus ABSCINT-206 for cardiac sarcoidosis) for whole-body molecular imaging, currently pre-revenue and conducting a Phase IIb HERMIA trial.
- Ownership category
- akta.pro rank
Abscint industry classification
Industry- Product category
- Molecular Imaging Diagnostics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA)
- akta.pro secondary industry
- Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE)
Keywords
Where Abscint is headquartered
LocationHeadquarters
- HQ city
- Ganshoren
- HQ country
- Belgium
- HQ region
- Europe
Offices1 record
Markets served
Abscint business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- GMP Grade Precursor Sales: ABSCINT offers GMP grade precursor to academic institutes, hospitals, and companies for investigator-initiated trials. This represents a potential revenue stream for clinical study access.
- Diagnostic Imaging Products: The company is developing radiopharmaceutical diagnostics for cancer detection, treatment selection, and monitoring. Once regulatory approval is obtained, commercial sales of the PET tracer products will be the primary revenue source.
- Technology Licensing: ABSCINT has licensed patent rights for diagnostic applications from VUB. The company may generate licensing revenue from its HER2 imaging technology platform.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Abscint product offering
Product offeringCore offering
Abscint develops radiolabeled single-domain antibody (sdAb) based PET tracers for in-vivo molecular imaging diagnostics. Its lead product, 68Ga-HER2 (ABS011), is a Gallium-68 labeled anti-HER2 PET tracer enabling whole-body imaging of HER2-expressing tumors in breast cancer patients. The company also has a second clinical-stage program, ABSCINT-206, for cardiac sarcoidosis detection, and supplies GMP-grade precursor material to academic institutes and hospitals for investigator-initiated clinical trials.
Product overview
ABSCINT is a clinical-stage molecular imaging company developing radiopharmaceutical diagnostics based on radiolabeled single-domain antibodies (sdAbs) for whole-body molecular imaging. The company's lead product is 68Ga-HER2 (ABS011), a PET tracer for HER2 imaging in breast cancer, currently in Phase IIb clinical trials through the HERMIA study. ABSCINT also has a second clinical-stage program, ABSCINT-206, for cardiac sarcoidosis detection. The company offers a GMP precursor access program enabling investigator-initiated trials. The technology platform uses single-domain antibodies (12-15 kDa) labeled with short-half-life radioisotopes (such as gallium-68) for precise, whole-body imaging within 60-90 minutes post-injection, enabling diagnosis, treatment selection, and treatment response monitoring.
Differentiator
Problem solved
Functional benefit
Products and services
- 68Ga-HER2 (ABS011)
- ABSCINT-206
- GMP Precursor Access Program
Quantifiable outcome
- 34.4% of patients had their treatment plans modified based on HER2 PET/CT results
- +3 more outcomes
Companies that use Abscint
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Abscint technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Abscint partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered major and core.
- Institut Jules BordetmajorLeading Belgian cancer research institute and clinical trial site. Participating in HERMIA clinical trial evaluating 68Ga-ABS011 PET/CT in breast cancer patients. Located in Anderlecht, Belgium.
- UZ BrusselmajorUniversity Hospital Brussels with 3,800+ staff and 721 beds. Clinical trial site for HERMIA study and investor in ABSCINT. Research partner with teaching mission connected to VUB.
- UZ LeuvenmajorUniversity Hospitals Leuven, major Belgian academic medical center. Clinical trial site for HERMIA study evaluating ABSCINT-HER2 imaging technology.
- Vrije Universiteit Brussel (VUB)coreABSCINT is a spin-off from VUB. Technology based on joint research efforts of Prof. Dr. Tony Lahoutte at VUB and Prof. Dr. Jo Van Ginderachter at VIB-VUB Center for Inflammation Research. VUB licensed patent for diagnostic applications to ABSCINT.
- VIBcoreVIB is an independent research institute where top scientists conduct pioneering basic research. Joint research efforts with VUB team of Prof. Jo Van Ginderachter at VIB-VUB Center for Inflammation Research contributed to ABSCINT's technology platform.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Abscint competitors and assessment
Company assessmentDirect peers
- Precirix: Precirix develops single-domain antibody (sdAb)-based radiopharmaceuticals for cancer imaging, including HER2-targeted and other oncology tracers. It is the most direct technology peer to Abscint, using the same camelid sdAb scaffold and a similar radiolabeling approach for PET imaging.
- ImaginAb: ImaginAb is a clinical-stage immuno-imaging company using camelid single-domain antibodies (nanobodies) to develop diagnostic imaging agents for oncology, immunology, and other diseases. Direct peer based on shared sdAb platform and PET/SPECT imaging focus.
Broad incumbents
- Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company with multiple approved and late-stage imaging products (e.g., Illuccix for PSMA PET) and a growing theranostic pipeline. It competes broadly in the molecular imaging space and represents the kind of scaled player AbscINT would need to position against in HER2 imaging.
- Lantheus Holdings: Lantheus is an established radiopharmaceutical company with commercial diagnostic products (e.g., Pylarify for PSMA PET imaging) and a growing pipeline. Comparable as a broad incumbent in radiodiagnostics with similar end-customer focus on hospital nuclear medicine departments.
- Curium Pharma: Curium is one of the largest nuclear medicine companies globally, producing and distributing SPECT and PET radiopharmaceuticals across a broad portfolio. Comparable as a large incumbent supplying diagnostic tracers to hospital networks that Abscint also targets.
- GE HealthCare: GE HealthCare is a global medical imaging and nuclear medicine leader, including PET radiotracer production (e.g., 18F-FDG) and a broad portfolio of molecular imaging agents. Broad incumbent comparable on the nuclear medicine / PET imaging value chain that Abscint's tracers plug into.
- Bracco Imaging: Bracco Imaging is a global diagnostic imaging company offering contrast agents and radiopharmaceuticals for MRI, CT, ultrasound, and nuclear medicine. Broad incumbent with overlapping end customers (hospitals, imaging centers) where Abscint's HER2 PET tracer would be administered.
Emerging players
- Ratio Therapeutics: Ratio Therapeutics is an emerging radiopharmaceutical company developing targeted radioconjugates for both imaging and therapy in oncology. Comparable as a smaller, earlier-stage peer operating in the same radiopharmaceutical space with potential overlap in HER2 and other oncology targets.
Others
- Cardinal Health Nuclear & Precision Health Solutions: Cardinal Health operates one of the largest radiopharmaceutical distribution networks in the US, supplying unit-dose radiopharmaceuticals to hospitals and clinics. Comparable as a key distribution/infrastructure channel in the radiopharma value chain that Abscint's products would rely on for US scaling.
- Novartis (Radioligand Therapy franchise): Novartis commercializes the radioligand therapies Lutathera and Pluvicto and is investing heavily in radioligand imaging companion diagnostics. Comparable as an adjacent incumbent shaping the broader radioligand diagnostic/theranostic landscape in which Abscint's HER2 imaging technology sits.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Abscint social profiles
Digital presenceAbscint financial estimates
Financial estimateRevenue estimate
Valuation estimate
Abscint leadership team
Management profileNumber of profiles
Profiles7 records
Abscint funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Abscint M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Abscint
What does Abscint do?
Abscint develops radiolabeled single-domain antibody (sdAb) based PET tracers for in-vivo molecular imaging diagnostics. Its lead product, 68Ga-HER2 (ABS011), is a Gallium-68 labeled anti-HER2 PET tracer enabling whole-body imaging of HER2-expressing tumors in breast cancer patients. The company also has a second clinical-stage program, ABSCINT-206, for cardiac sarcoidosis detection, and supplies GMP-grade precursor material to academic institutes and hospitals for investigator-initiated clinical trials.
Is Abscint a public or private company?
Abscint is a private company. It is classified as venture growth investor backed and is currently operating.
When was Abscint founded?
Abscint was founded in 2022. It employs 1 to 10 people.
Where is Abscint based?
Abscint is headquartered in Ganshoren, Belgium, in the Europe region.
How does Abscint make money?
Three revenue lines are on record. GMP Grade Precursor Sales are the primary driver. The others are diagnostic Imaging Products and technology Licensing.
Who are Abscint's main competitors?
Direct peers on record are Precirix and ImaginAb. Broad incumbents are Telix Pharmaceuticals, Lantheus Holdings, Curium Pharma, GE HealthCare and Bracco Imaging. Ratio Therapeutics is listed as an emerging player. Others are Cardinal Health Nuclear & Precision Health Solutions and Novartis (Radioligand Therapy franchise).
Does Abscint have an API?
No public API is recorded for Abscint.
What industry is Abscint in?
Abscint's product category is Molecular Imaging Diagnostics. Its primary akta.pro industry code is HLAIAGAA, Diagnostic Radiopharmaceuticals (SPECT/PET Tracers), with a secondary code of EUAKAIAE, Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain). Its NAICS code is 325412 and its SIC code is 2835.